Bristol Myers Squibb faces a $6.7 billion lawsuit for allegedly delaying drug approvals, cheating former Celgene shareholders. The lawsuit claims the delay cost shareholders an extra $9 per share in cash. UMB Bank, now confirmed as trustee, filed the lawsuit after a previous dismissal.